An €8 million European research initiative is set to bankroll a Phase 2 clinical trial for HER-096, an experimental therapy targeting the progression of Parkinson’s disease.
The project, dubbed HERMOD, plans to recruit 100 newly diagnosed patients to test the drug’s safety and efficacy, according to Parkinson’s News Today.
Funding the clinical pipeline
The consortium draws its financial backing from the European Union’s Horizon Europe research and innovation program. By aligning industry, academic, and clinical partners, the group intends to build a body of evidence to steer future development paths for the drug.
“This project will help us evaluate the potential of HER-096 in people with Parkinson’s disease and generate important evidence to support future development decisions,” Antti Vuolanto, Herantis Pharma, said.
Mimicking natural neuroprotection
Parkinson’s disease hinges on the death of dopaminergic neurons, the cells tasked with dopamine production. HER-096, a lab-engineered derivative of cerebral dopamine neurotrophic factor (CDNF), attempts to replicate a protein that naturally aids nerve cell recovery and survival.
Administered through subcutaneous injection, the therapy targets cellular energy production, inflammation, and proteostasis—the cellular mechanism for managing protein clearance. Preclinical data suggest these pathways are critical to the drug’s function.
Digital monitoring in Phase 2
The upcoming trial will randomize participants to receive either the active treatment or a placebo for 36 weeks. Following this, all participants will switch to HER-096 for a 24-week period. To capture data with higher precision than standard assessments, researchers will employ smartphone-based digital biomarkers to monitor motor performance.
“By combining scientific excellence, clinical expertise and cross-sector collaboration, we aim to generate knowledge that may help improve the lives of people living with this condition,” said Rejko Krüger, MD, principal investigator at the Luxembourg Institute of Health and Centre Hospitalier de Luxembourg.
HER-096 shows promise in Phase 1b trial
The therapy showed promise in a Phase 1b trial (NCT06659562), where it was well tolerated by both healthy volunteers and Parkinson’s patients. Reported side effects were largely restricted to mild-to-moderate injection site reactions.
The research team expects to file a clinical trial application by the end of this year. Provided the project clears regulatory and financing hurdles, investigators plan to administer the first dose to a participant in the first half of 2027.
Ultimately, the HERMOD consortium seeks to determine if HER-096 can modify the trajectory of Parkinson’s disease rather than merely masking its symptoms.